Phi Optics, Inc. is an optical microscopy company organized around empowering bio-pharma and life sciences academia researchers with a disruptive technology Quantitative Phase Imaging (QPI) that provides highly accurate, fast and inexpensive imaging of live cells and tissues. With live cells hard to image because of lack of contrast, current instrumentation requires cells to be fixed or dead (AFM/SEM) or is toxic in the long term (Fluorescence). The companys product is an electro-optic device that attaches to new and existing research grade optical microscopes and provides faster and more sensitive imaging of live cells and tissues than currently possible with the state-of-the-art technology. Phi Optics instruments are targeted to the work of investigators where live cell imaging is the main method of observation: fundamental cell science, disease identification, drug discovery, embryo and stem cells manipulation. Phi Optics patented disruptive technology - Spatial Light Interference Microscopy (SLIM) - provides faster and more sensitive imaging of live cells and tissues than currently possible with the state-of-the-art technology. The firm's label free and quantitative imaging technology with nanoscale sensitivity have applications in life sciences, diagnostic pathology, and nanotechnology markets.
